据韩国官方周三公布的数据显示， 受到结婚率上升和人口结构变化的影响，韩国4月份出生人口同 比增幅达到34年来的最高水平。 与此同时，出生于1991年至1995年间的韩国人如今年龄在29至34岁之间，这一庞大人群正进 入婚姻和生育的黄金年龄。数据显示，30至34岁女性的数量从2020年的151万人增加到今年5 月的165万人。 这些因素推动了结婚率和出生率的上升，但韩国官员们对于这一趋势是否可持续仍持怀疑态 度。一些专家指出，韩国人口的危机与飙升的住房成本、激烈的教育竞争、苛刻的工作文化以 及年轻一代对婚姻和家庭生活态度的改变有关。 联合国最近的一份报告则将韩国列为"超低生育率"国家之一，并认为韩国在未来三十年内很难 将总和生育率恢复至可完成代际更替的水平，估计恢复的可能性仅有0.1%。 人口问题也成为困扰韩国经济的一大难点。为此，韩国政府乃至各大公司都发起了一些行动来 扭转局势，比如韩国政府为1岁以下婴儿提供每月30万韩元（约1740人民币）的育儿津贴，并 为父母提供更多的育儿假。 首尔国立大学经济学家Hong Sok-chul向媒体表示，虽然政府的政策似乎旨在降低与结婚和生 育相关的成本，但他怀疑财政激励是 ...

Core Viewpoint - The medical beauty industry is experiencing a significant performance divergence among listed companies, driven by a shift from hyaluronic acid to collagen products, indicating a potential restructuring of industry value logic [1][3]. Group 1: Performance Analysis - In 2024, the performance of upstream medical beauty companies showed significant divergence, with companies like Juzi Biological and Jinbo Biological leading with high growth rates, while major hyaluronic acid players like Aimeike, Huaxi Biological, and Haohai Biological faced pressure [2][3]. - Aimeike's revenue growth slowed to 5.45%, the lowest since its listing, while Huaxi Biological's revenue declined by 11.61% and net profit dropped by 70.59% [3][5]. - Juzi Biological achieved revenue of 5.539 billion, a year-on-year increase of 57.2%, and a net profit of 2.062 billion, up 42.4% [5][7]. Group 2: Market Trends - The market for recombinant collagen products in China is projected to grow from 18.5 billion in 2022 to 108.3 billion by 2027, with a compound annual growth rate of 42.4% [7]. - Companies are increasingly entering the collagen market, including Aimeike and Huaxi Biological, which are exploring new opportunities in this segment [7][8]. - Huaxi Biological is developing proprietary recombinant human collagen products that have entered clinical trials, indicating a strategic shift towards innovative product development [7].